Senior Vice President, Global R&D, Pfizer Consumer Healthcare
Watch the Transform 2013 Digging In session "How Do We Empower People in Their Own Care?"
Mark Gelbert, Ph.D., J.D., leads all aspects of the Pfizer Consumer Division's Global Research & Development (R&D) organization. He is responsible for driving and prioritizing the division's R&D efforts to effectively bring new products to market and manage the increasingly challenging regulatory environment for over-the-counter (OTC) products.
As chairman of the GLT Rx-to-OTC Switch Steering Committee, Dr. Gelbert oversees the prioritization and progress of Pfizer's switch programs. In his role, he drives alignment at the leadership level while ensuring that the right resources are in place and the right stakeholders are involved along the way.
Before joining Pfizer, Dr. Gelbert was vice president of global R&D for Johnson & Johnson Consumer Health Care. He has also held senior R&D positions with Pfizer Consumer Healthcare, Schering-Plough Healthcare and Novartis Consumer Health. Dr. Gelbert has been responsible for the development of many consumer health care products on the shelf today, including the Rx-to-OTC switches of Claritin, Lamisil, Zantac150 and Lotrimin Ultra.
Dr. Gelbert began his career in product development in Procter & Gamble's Health Care Division. While at Procter & Gamble, he completed his law degree and focused his efforts in drug regulatory affairs. In addition to his law degree, Dr. Gelbert has a B.A. from Rutgers University, as well as an M.S. and Ph.D. in chemistry from the University of Massachusetts Amherst.
He has held leadership positions in a number of professional organizations, including the Consumer Healthcare Products Association, where he was chair of the Scientific Affairs Committee and a member of the board of directors. He is admitted to the Ohio State Bar Association and Southern District of Ohio federal bar.
Oct. 16, 2013